Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 10/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SLC26A6 | Q9BXS9 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25801838 | 0.95 | SIRT2 (0.33) | TRPA1LMNAPPARGPPARACYP1A2 | |
| SCHEMBL25801850 | 0.93 | L3MBTL1 (0.33) | SMN1; SMN2MAPT | |
| SCHEMBL25801881 | 0.93 | L3MBTL1 (0.33) | TRPA1CYP1A2CYP2D6SMN1; SMN2 | |
| SCHEMBL23578499 | 0.92 | TRPA1 (0.37) | TRPA1LMNAPPARGPPARASLC26A6 | |
| SCHEMBL25801748 | 0.92 | MAPT (0.41) | TRPA1LMNACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL25801784 | 0.89 | MAPT (0.39) | LMNAPPARGPPARACYP1A2CYP2D6 | |
| SCHEMBL25804964 | 0.86 | SIRT2 (0.33) | TRPA1LMNAPPARGPPARASLC26A6 | |
| SCHEMBL25801972 | 0.86 | MEN1 (0.35) | LMNASMN1; SMN2MAPT | |
| SCHEMBL25801777 | 0.84 | MEN1 (0.35) | LMNAMAPT | |
| SCHEMBL25801774 | 0.84 | KMT2A (0.36) | LMNAPPARGPPARACYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | CPA2, RO60, C5AR1 | TRPA1 4592/4885LMNA 3388/4885PPARG 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.